Table 1.
Patient and donor characteristics
| Parameter | Total cohort | Strong inhibiting KIR3DL1 | Weak/noninhibiting KIR3DL1 | P* | |||
|---|---|---|---|---|---|---|---|
| No. of patients | 2222 | (100) | 574† | (100) | 1630† | (100) | |
| Patient sex | |||||||
| Male | 1275 | (57.4) | 328 | (57.1) | 937 | (57.5) | |
| Female | 947 | (42.6) | 246 | (42.9) | 693 | (42.5) | .9 |
| Age at HCT, y | |||||||
| Median | 59.3 | 59.6 | 59.2 | ||||
| IQR | 49.8-65.6 | 50.1-65.8 | 49.7-65.5 | ||||
| Range | 18.1-79.6 | 18.4-79.6 | 18.1-78.6 | .5 | |||
| Disease | |||||||
| AML | 1773 | (79.8) | 472 | (82.2) | 1286 | (78.9) | |
| MDS | 449 | (20.2) | 102 | (17.8) | 344 | (21.1) | .09 |
| Disease risk | |||||||
| Low | 1 | (0.05) | 0 | (0) | 1 | (0.06) | |
| Intermediate | 1308 | (58.9) | 326 | (56.8) | 970 | (59.5) | |
| High | 906 | (40.8) | 248 | (43.2) | 652 | (40.0) | |
| Very high | 7 | (0.3) | 0 | (0) | 7 | (0.4) | .2 |
| Karnofsky performance status | |||||||
| 90%-100% | 1517 | (68.3) | 386 | (67.2) | 1118 | (68.6) | |
| 80% | 451 | (20.3) | 126 | (22.0) | 322 | (19.8) | |
| ≤80% | 116 | (5.2) | 28 | (4.9) | 87 | (5.3) | |
| Missing information | 138 | (6.2) | 34 | (5.9) | 103 | (6.3) | .7 |
| Donor age, y | |||||||
| Median | 31 | 32 | 31 | ||||
| IQR | 25-40 | 25-42 | 25-39 | ||||
| Range | 18-60 | 18-58 | 18-60 | .8 | |||
| HLA match | |||||||
| 10/10 matched | 1727 | (77.7) | 422 | (73.5) | 1291 | (79.2) | |
| 9/10 (DQB1 mm) | 63 | (2.8) | 17 | (3.0) | 45 | (2.8) | |
| 9/10 (A, B, C, or DRB1 mm) | 417 | (18.8) | 131 | (22.8) | 283 | (17.4) | |
| 8/10 matched | 15 | (0.7) | 4 | (0.7) | 11 | (0.7) | .04 |
| Patient–donor sex constellation | |||||||
| Male–male | 1077 | (48.5) | 284 | (49.5) | 786 | (48.2) | |
| Male–female | 198 | (8.9) | 44 | (7.7) | 151 | (9.3) | |
| Female–male | 644 | (29.0) | 169 | (29.4) | 470 | (28.8) | |
| Female–female | 303 | (13.6) | 77 | (13.4) | 223 | (13.7) | .7 |
| Patient–donor CMV serostatus | |||||||
| Negative–negative | 725 | (32.6) | 169 | (29.4) | 549 | (33.7) | |
| Negative–positive | 159 | (7.2) | 52 | (9.1) | 106 | (6.5) | |
| Positive–negative | 506 | (22.8) | 130 | (22.6) | 371 | (22.8) | |
| Positive–positive | 812 | (36.5) | 219 | (38.2) | 588 | (36.1) | |
| Missing information | 20 | (0.9) | 4 | (0.7) | 16 | (1.0) | .13 |
| T-cell depletion | |||||||
| No T-cell depletion | 432 | (19.4) | 106 | (18.5) | 323 | (19.8) | |
| ATG | 1724 | (77.6) | 456 | (79.4) | 1254 | (76.9) | |
| Alemtuzumab | 51 | (2.3) | 9 | (1.6) | 41 | (2.5) | |
| Ex vivo T-cell depletion | 15 | (0.7) | 3 | (0.5) | 12 | (0.7) | .4 |
| Conditioning intensity | |||||||
| Myeloablative | 436 | (19.6) | 106 | (18.5) | 328 | (20.1) | |
| Reduced | 1694 | (76.2) | 443 | (77.2) | 1235 | (75.8) | |
| Nonmyeloablative | 83 | (3.7) | 21 | (3.7) | 62 | (3.8) | |
| Missing information | 9 | (0.4) | 4 | (0.7) | 5 | (0.3) | .5 |
| Conditioning | |||||||
| TBI-based | 531 | (23.9) | 132 | (23.0) | 397 | (24.4) | .6 |
| Chemotherapy-based | 1689 | (76.0) | 441 | (76.8) | 1232 | (75.6) | |
| Missing information | 2 | (0.09) | 1 | (0.17) | 1 | (0.06) | |
| Graft source | |||||||
| PBSC | 2124 | (95.6) | 548 | (95.5) | 1559 | (95.6) | |
| Bone marrow | 98 | (4.4) | 26 | (4.5) | 71 | (4.4) | .9 |
| Year of HCT | |||||||
| 2005-2009 | 208 | (9.4) | 44 | (7.7) | 164 | (10.1) | |
| 2010-2013 | 493 | (22.2) | 120 | (20.9) | 369 | (22.6) | |
| 2014-2017 | 1521 | (68.5) | 410 | (71.4) | 1097 | (67.3) | .12 |
Data are presented as no. (%) unless otherwise indicated. CMV, cytomegalovirus; IQR, interquartile range; TBI, total body irradiation.
*
Pearson χ2 test of independence or Mann-Whitney U test for categorical or continuous parameters, respectively, to test whether the distributions differ between patients with a strong inhibiting KIR3DL1 donor and patients with a weak/noninhibiting KIR3DL1 donor.
†
Patients were classified according to the algorithms published by Boudreau et al19 in 2017. Numbers of patients grouped according to their donors’ KIR3DL1/HLA-B subtype combination do not add up to the total number because 18 patients could not be classified according to the algorithm.